Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. (Q38737680)
Jump to navigation
Jump to search
scientific article published on 02 June 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. |
scientific article published on 02 June 2017 |
Statements
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial (English)
Michael A Davies
Philippe Saiag
Thierry Lesimple
Stergios J Moschos
David Hogg
Michele Del Vecchio
Céleste Lebbé
Ying Zhang
Yingjie Huang
Bijoyesh Mookerjee
Caroline Robert
Jean-Jacques Grob
Keith T Flaherty